These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21383525)

  • 1. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Takami HE
    Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
    Covell LL; Ganti AK
    Target Oncol; 2015 Sep; 10(3):311-24. PubMed ID: 26335853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New therapeutic options for advanced thyroid cancer].
    Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted molecular therapies in thyroid carcinoma.
    Romagnoli S; Moretti S; Voce P; Puxeddu E
    Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving field of kinase inhibitors in thyroid cancer.
    Marotta V; Sciammarella C; Vitale M; Colao A; Faggiano A
    Crit Rev Oncol Hematol; 2015 Jan; 93(1):60-73. PubMed ID: 25240824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early clinical studies of novel therapies for thyroid cancers.
    Sherman SI
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors and the thyroid.
    Sherman SI
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid carcinoma, version 2.2014.
    Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
    J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of molecular targeted drugs for advanced thyroid cancer in Japan.
    Takami H; Ito K; Sugino K
    Endocr J; 2014; 61(9):833-9. PubMed ID: 24849385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced thyroid cancers: new era of treatment.
    Mohammed AA; El-Shentenawy A
    Med Oncol; 2014 Jul; 31(7):49. PubMed ID: 24908065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and clinical results of multi-target treatments in oncology.
    Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
    Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies for thyroid cancer.
    Krajewska J; Jarzab B
    Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.